Some studies have shown that the KIT mutation is significantly associated with decreased remission duration and overall survival (OS) in CBF-AML patients [4, 5, 8–12], whereas other studies have shown that KIT mutations have no obvious effect on CBF-AML clinical outcomes as a group or in subgroups [7, 13–17]. Here, CEBPZ is linked to acute myeloid leukemia.